Roche Holding Ltd/ CH0012032113 /
09/09/2024 21:50:36 | Chg. -19.8480 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
327.1520USD | -5.72% | 35 Turnover: 12,124.7520 |
-Bid Size: - | -Ask Size: - | 293.74 bill.USD | - | - |
GlobeNewswire
26/08
First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborat...
GlobeNewswire
08/08
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
GlobeNewswire
08/08
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Updat...
GlobeNewswire
18/06
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
14/06
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon...
GlobeNewswire
11/06
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
09/05
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
03/04
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Inju...
GlobeNewswire
02/04
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire
22/03
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highl...
GlobeNewswire
14/03
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides C...
GlobeNewswire
26/02
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Ro...
GlobeNewswire
21/02
REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Rep...